My Treatments

I had a post and links in my old blog to the medication regimen I was on and why. It appears I have lost that and I would like to re-create it. Noexcuses link to the sinugalair studies was a good remind so why not start with that one and I will add the rest in later.

Singulair before bed. Anything that cuts down and allergies and inflammation is for me since I think that is the biggest component of my problems at least for now.

Singulair in CF

from NoExcuses by NoExcuses
Ann Allergy Asthma Immunol. 2002 Dec;89(6):599-605.Links
Comment in:
Respir Med. 2007 Mar;101(3):684.
Anti-inflammatory effects of montelukast in mild cystic fibrosis.
Schmitt-Grohé S, Eickmeier O, Schubert R, Bez C, Zielen S.
Children's Hospital Medical Center, University of Bonn, Bonn, Germany. s.schmitt.grohe@uni-bonn.de

BACKGROUND: Immune-mediated inflammation contributes to progressive pulmonary damage in cystic fibrosis (CF). Sputum cysteinyl leukotriene levels, eosinophil cationic protein (ECP), and interleukin-8 (IL-8) are significantly related to disease severity.
OBJECTIVE: The aim of this study was to evaluate the anti-inflammatory and clinical effects of the cysteinyl leukotriene receptor antagonist montelukast in children with CF.
METHODS: A double-blind, randomized, crossover design was used. Patients received montelukast (6 to < or =" 14"> 14 years, 10 mg) or placebo as a once-daily tablet for 21 days and then, after a washout period of at least 4 weeks, crossed over to receive the alternative treatment. Blood and native nasal fluid were taken on days 1 and 21 of each treatment block, and WBC count, ECP, and IL-8 were analyzed using a chemiluminescent immunometric assay.
RESULTS: Sixteen CF patients (10 boys, 6 girls; age, 5 to 18 years, median 9.5 years) completed the trial. There was a significant (P < or =" 0.02)" or =" 0.027;">

CONCLUSIONS: Montelukast (ie SINGULAIR) reduces eosinophilic inflammation in CF patients. Multicenter trials providing more patients to create more data to prove the hypothesis that montelukast is an effective tool to cut down disease severity in CF patients are needed.